A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%
研究概览
简要总结
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is 18 years of age or old
- •Participant must meet one of the following:
- •Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I
- •Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan
- •Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra
- •Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi PET scan in the Nuclear Medicine Clinic
- •Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic
排除标准
- •Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes
- •Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.
研究组 & 干预措施
Thyroid cancer/nodal metastasis
Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
干预措施: Cerenkov luminescence imaging. (Diagnostic Test)
结局指标
主要结局
Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%
时间窗: Through study completion, an average of 24 hours
The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.
次要结局
未报告次要终点